Opdivo's Subcutaneous Formulation Shows Promise in Advanced Kidney Cancer: Bristol Myers Squibb's Latest Findings
Portfolio Pulse from Vandana Singh
Bristol Myers Squibb Co (BMY) has released positive topline data from a Phase 3 trial of a subcutaneous formulation of Opdivo for advanced kidney cancer. The formulation uses Halozyme Therapeutics Inc.'s (HALO) recombinant human hyaluronidase. The study met its primary and secondary endpoints. Earlier this month, BMY agreed to acquire Mirati Therapeutics Inc (MRTX) for $4.8 billion.
October 19, 2023 | 2:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb's successful trial of subcutaneous Opdivo could boost its stock.
The successful trial results could lead to increased demand for Opdivo, potentially boosting BMY's revenues and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Halozyme Therapeutics' technology was used in the successful trial of Bristol Myers Squibb's Opdivo.
The successful use of HALO's technology in the trial could lead to increased demand for its products, potentially boosting its stock price.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Bristol Myers Squibb's acquisition of Mirati Therapeutics could impact MRTX's stock.
The acquisition by BMY could lead to increased value for MRTX's shareholders, potentially boosting its stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50